<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594371</url>
  </required_header>
  <id_info>
    <org_study_id>KX-ORAX-001</org_study_id>
    <nct_id>NCT02594371</nct_id>
  </id_info>
  <brief_title>Ph3 Study To Determine Safety,Tolerability&amp;Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinex Pharmaceuticals Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athenex, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic
      breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, open-label, randomized, multicenter study in approximately 360 adult
      female subjects with histologically- or cytologically-confirmed breast cancer that is
      metastatic for whom treatment with IV paclitaxel monotherapy has been recommended by their
      oncologist. Approximately 400 subjects will be enrolled to provide 360 evaluable subjects.
      The subjects must have measurable metastatic target lesion disease as per RECIST v1.1
      criteria. Subjects will be randomized in a 2:1 ratio to either Oraxol or IV paclitaxel (as
      Taxol or generic).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response as determined by response criteria</measure>
    <time_frame>19 to 22 weeks</time_frame>
    <description>Tumor response is evaluated using the response evaluation criteria in solid tumors (RECIST v1.1 criteria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).]</time_frame>
    <description>Safety assessments will consist of determining and recording all AEs and SAEs; laboratory evaluation of hematology, blood chemistry, and urine analyses; periodic measurement of vital signs and electrocardiograms (ECGs); and the performance of physical examinations, as detailed in the schedule of procedures and assessments of the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).</time_frame>
    <description>The endpoint of progression-free survival is defined as not having died or progression of disease. Lost to follow-up will be considered as censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).</time_frame>
    <description>The endpoint of overall survival is defined as death, confirmed alive, and lost to follow-up. Alive and lost to follow-up will be considered as censored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Oraxol (paclitaxel + HM30181AK-US)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oraxol paclitaxel - supplied as 30-mg capsules
Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV paclitaxel - supplied as Taxol or generic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraxol</intervention_name>
    <arm_group_label>Oraxol (paclitaxel + HM30181AK-US)</arm_group_label>
    <other_name>HM30181 methanesulfonate monohydrate</other_name>
    <other_name>Oral paclitaxel capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV paclitaxel</intervention_name>
    <arm_group_label>IV paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Women ≥18 years of age

          3. Histologically- or cytologically-confirmed breast cancer for whom IV paclitaxel (as
             Taxol or generic) monotherapy has been recommended by their oncologist

          4. Measurable metastatic target lesion disease measurable by CT scan as per RECIST v1.1
             criteria

          5. Adequate hematological status as demonstrated by not requiring granulocyte-colony
             stimulating factor (G-CSF) or transfusion support to achieve the following at
             Screening:

               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L

               -  Platelet count ≥100 x 109/L

               -  Hemoglobin ≥10 g/dL

          6. Adequate liver function as demonstrated by:

               -  Total bilirubin of ≤1.5 mg/dL

               -  Alanine aminotransferase and aspartate aminotransferase ≤3 x upper limit of
                  normal (ULN) or ≤5 x ULN if liver metastasis is present

               -  Alkaline phosphatase ≤3 x ULN or ≤5 x ULN if bone metastasis is present

          7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          9. Life expectancy of at least 6 months, in the judgement of the investigator

         10. Subjects must be postmenopausal (≥12 months without menses) or surgically sterile (ie,
             by hysterectomy and/or bilateral oophorectomy) or must be using effective
             contraception and agree to used of contraception for 30 days after their last dose of
             assigned study treatment.

         11. Subjects who are of childbearing potential must have a negative screening serum
             pregnancy test.

        Exclusion Criteria:

          1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or
             previous investigational products

          2. If previously treated with a taxane (paclitaxel or docetaxel) as part of
             anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject
             relapsed less than 1 year following treatment

          3. Only evidence of metastatic disease is to bone or other nontarget or nonmeasurable
             lesions (including, for example, ascites or plural effusion) according to RECIST v1.1
             criteria

          4. Central nervous system metastasis, including leptomeningeal involvement

          5. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever
             is longer

          6. Are currently receiving other medications intended for the treatment of their
             malignancy

          7. Received radiation therapy within 2 weeks prior to signing informed consent and those
             for whom radiation therapy is planned within 6 months from the time of signing
             informed consent

          8. Women who are pregnant or breastfeeding

          9. Taking a medication known to be a strong P-gp inhibitor or inducer within 14 days of
             starting treatment

         10. Taking an oral medication with a narrow therapeutic index known to be a P-gp substrate
             within 24 hours prior to start of treatment

         11. Taking a medication known to be a strong cytochrome P450 (CYP) 3A4 inhibitor (eg,
             ketoconazole) or inducer (eg, rifampin or St. John's Wort) within 14 days of starting
             treatment

         12. Taking a medication known to be a strong inhibitor (eg, gemfibrozil) or inducer (eg,
             rifampin) of CYP2C8 within 14 days of starting treatment

         13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, myocardial infarction within the last
             6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease
             requiring oxygen, known bleeding disorders, or any concomitant illness or social
             situation that would limit compliance with study requirements

         14. Major surgery to the upper GI tract, or have a history of GI disease or other medical
             condition that, in the opinion of the Investigator may interfere with oral drug
             absorption

         15. History of significant hypersensitivity-type reactions to paclitaxel or Cremophor EL
             (polyoxyl 35 castor oil, NF) that would contraindicate the use of IV paclitaxel
             formulated with Cremophor EL

         16. Known allergic reaction or intolerance to contrast media

         17. Documented history of true systemic allergic reaction to 3 or more medications

         18. For whom the Investigator believes that participation in this study would not be
             acceptable
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cutler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kinex Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Goldfinch, MBA</last_name>
    <phone>716-427-2837</phone>
    <email>jgoldfinch@kinexpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Investigacion Pergamino SA</name>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susana Kahl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONC</name>
      <address>
        <city>Ciudad de Córdoba</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Richardet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Privada Reina Fabiola</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago R Bella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Infinito</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Ortiz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Koriza</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Picon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>Rio Negro</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben D Kowalyszyn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>COIBA</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirta Varela</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMEDIC</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fundación Investigar</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fundación Centro Oncológico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego L Kaen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pastor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Tatangelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan J Zarba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAIPO</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe S Palazzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Arturo López Pérez</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Barajas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Referencia de Salud Cordillera Unidad de Patología Mamaria</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alonso U Obrador</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja Arriarán</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar D Castillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRAM</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro P Galaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Alemana Temuco</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología E.S.E.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo B Maya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Colombiana de Cancerología Clinica Vida</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nestor Eduardo L Quintero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Hospitalaria San Vicente de Paúl</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Alfredo A Gómez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hemato Oncologos S.A.</name>
      <address>
        <city>Valle</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Cristina A Rojas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Metropolitano de Santiago (HOMS)</name>
      <address>
        <city>Santiago de los Caballeros</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael G Pilarte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa H Veras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de la Plaza de la Salud</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Yadir Ramirez Marmol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital SOLCA</name>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayra P Maridueña</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Andrade Martín</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo D Molina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital SOLCA</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny C Guamán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Espemedic</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Jeovany R Marinero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Diagnotico Clinica Oncologica &amp; Cancer Research</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Finlander R Osegueda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Cancer Center</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Schaeffer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CELAN Clínica Médica</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Antonio Castro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Privada</name>
      <address>
        <city>Guatemala city</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen S Sarmiento</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Grupo Angeles, S.A.</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Raul Salguero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica en Guatemala</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Alejandra Zelada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRESEM</name>
      <address>
        <city>Quetzaltenango</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio R Velasquez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Excel Medica</name>
      <address>
        <city>Cortés</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyapa A Cáceres</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tecnología en Investigación</name>
      <address>
        <city>Cortés</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge H Sabillón</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hemato Oncológico Panamá</name>
      <address>
        <city>Panama city</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos A Velarde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Oncológica Miraflores</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge F Sanchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miro M Inocente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional del Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio G Doroteo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Dominican Republic</country>
    <country>Ecuador</country>
    <country>El Salvador</country>
    <country>Guatemala</country>
    <country>Honduras</country>
    <country>Panama</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

